Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin for Proteinuric Chronic Kidney Disease
NCT01831193Phase 3Completed
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Start
- Feb 2013
- Primary completion
- Apr 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of curcumin in proteinuria and chronic kidney disease (CKD), sponsored by Instituto Nacional de Cardiología Ignacio Chávez. Primary endpoint: Change in proteinuria at 8 weeks. Started Feb 2013; status: completed.
02
Drugs
curcumin
03
Conditions
proteinuriachronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01831193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01831193.